Biotech Values

[dewophile]

the data just released, which showed both viral suppression and statistically significant reductions in symptoms. The latter didn't happen with EDP-938

actually the latter did happen and EDP-938 showed stat significant reduction in symptoms in the challenge study. In fact the symptom scores vs placebo were almost identical for 938 vs 323, just that the antiviral effect of 323 was more robust. Which raises the distinct possibility that 938 may be enough in the clinic and there may be very little to gain with additional viral pressure on top of an already very potent drug

here is ENTA's updated slide deck w both data sets

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

totally agree the market reaction today and the last few months is totally just noise. Someone wants out of the stock for whatever reason given the selling of late but the prospects for the company have not changed IMO at least wrt pipeline (patent case I am clueless)